SG11202006125VA - Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors - Google Patents

Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors

Info

Publication number
SG11202006125VA
SG11202006125VA SG11202006125VA SG11202006125VA SG11202006125VA SG 11202006125V A SG11202006125V A SG 11202006125VA SG 11202006125V A SG11202006125V A SG 11202006125VA SG 11202006125V A SG11202006125V A SG 11202006125VA SG 11202006125V A SG11202006125V A SG 11202006125VA
Authority
SG
Singapore
Prior art keywords
pyridin
methyl
ghrelin
goat
inhibitors
Prior art date
Application number
SG11202006125VA
Other languages
English (en)
Inventor
Thomas Trieselmann
Cédrickx Godbout
Christoph Hoenke
Viktor Vintonyak
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of SG11202006125VA publication Critical patent/SG11202006125VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202006125VA 2018-02-02 2019-01-28 Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors SG11202006125VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18154824 2018-02-02
PCT/EP2019/051989 WO2019149657A1 (en) 2018-02-02 2019-01-28 Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors

Publications (1)

Publication Number Publication Date
SG11202006125VA true SG11202006125VA (en) 2020-07-29

Family

ID=61157050

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006125VA SG11202006125VA (en) 2018-02-02 2019-01-28 Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors

Country Status (21)

Country Link
US (1) US11254688B2 (ar)
EP (1) EP3746451B1 (ar)
JP (1) JP7015396B2 (ar)
KR (1) KR20200116978A (ar)
CN (1) CN111655700B (ar)
AU (1) AU2019215707A1 (ar)
BR (1) BR112020013082A2 (ar)
CA (1) CA3087826A1 (ar)
CL (1) CL2020001907A1 (ar)
CO (1) CO2020009299A2 (ar)
CR (1) CR20200332A (ar)
EA (1) EA202091805A1 (ar)
EC (1) ECSP20050785A (ar)
IL (1) IL276136A (ar)
JO (1) JOP20200190A1 (ar)
MA (1) MA53075A (ar)
MX (1) MX2020008053A (ar)
PE (1) PE20210174A1 (ar)
PH (1) PH12020551168A1 (ar)
SG (1) SG11202006125VA (ar)
WO (1) WO2019149657A1 (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017307033B2 (en) 2016-08-05 2020-11-26 Boehringer Ingelheim International Gmbh Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors
MA53075A (fr) 2018-02-02 2021-05-12 Boehringer Ingelheim Int Dérivés d'oxadiazolopyridine à substitution benzyle, (pyridin-3-yl)méthyle ou (pyridin-4-yl)méthyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat)
US11583532B2 (en) 2018-02-02 2023-02-21 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (GOAT) inhibitors
JP7225253B2 (ja) * 2018-02-02 2023-02-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのピラゾール置換及びインダゾール置換オキサジアゾロピリジン誘導体
EP4153600A1 (en) 2020-05-22 2023-03-29 Boehringer Ingelheim International GmbH Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
EP4153599B1 (en) 2020-05-22 2024-03-13 Boehringer Ingelheim International GmbH Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
WO2023114472A1 (en) * 2021-12-16 2023-06-22 Icahn School Of Medicine At Mount Sinai Heterocyclic compounds as 5ht2a biased agonists
CN114426516B (zh) * 2022-02-16 2022-11-04 安徽有吉医药科技有限公司 一种2-氨基-3-溴吡啶的制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004082383A1 (en) 2003-03-17 2004-09-30 Basf Aktiengesellschaft Use of triazolopyrimidines for combating nematode diseases of plants
EP2043634A2 (en) 2006-07-12 2009-04-08 Merck & Co., Inc. Substituted pyrazoles as ghrelin receptor antagonists
KR20090119876A (ko) 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
HUE059861T2 (hu) 2007-04-11 2023-01-28 Canbas Co Ltd N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
WO2008141843A1 (en) 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors
EP2158214B1 (en) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
FR2934058B1 (fr) 2008-07-15 2010-09-24 Centre Nat Rech Scient Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines
FR2933989B1 (fr) 2008-07-16 2013-03-08 Commissariat Energie Atomique Procede de purification de microorganismes presents dans des echantillons liquides
FR2933975B1 (fr) 2008-07-17 2011-02-18 Servier Lab Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.
JP5635532B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
WO2010070251A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
BRPI0823376A2 (pt) 2008-12-15 2015-06-16 Zealand Pharma As Análagos de glucagon
CA2747155A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
US20110078154A1 (en) 2009-09-28 2011-03-31 Accenture Global Services Gmbh Recruitment screening tool
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
CA2802897A1 (en) 2010-06-24 2011-12-29 Zealand Pharma A/S Glucagon analogues
MX2014007120A (es) 2011-12-23 2015-03-05 Boehringer Ingelheim Int Analogos de glucagon.
CN104254525B (zh) 2012-02-24 2016-05-25 武田药品工业株式会社 芳环化合物
WO2013192388A1 (en) * 2012-06-20 2013-12-27 University Of Virginia Patent Foundation Compositions and methods for regulating glucose homeostasis and insulin action
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA118034C2 (uk) 2013-11-14 2018-11-12 Елі Ліллі Енд Компані Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази
EP3193939A4 (en) 2014-09-17 2018-10-24 The Regents of The University of California Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
US10131642B1 (en) * 2015-01-30 2018-11-20 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
AR104672A1 (es) * 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
AR104673A1 (es) 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
JP6957460B2 (ja) 2015-10-22 2021-11-02 カビオン・インコーポレイテッドＣａｖｉｏｎ， Ｉｎｃ． アンジェルマン症候群および関連する障害の処置方法
AU2017307033B2 (en) 2016-08-05 2020-11-26 Boehringer Ingelheim International Gmbh Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors
WO2018029545A1 (en) 2016-08-11 2018-02-15 Cellix Bio Private Limited Compositions and methods for the treatment of irritable bowel syndrome
EP3504185B1 (en) 2016-08-29 2021-11-24 Merck Sharp & Dohme Corp. Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
KR20200118124A (ko) 2018-02-02 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 그렐린 o-아실 트랜스퍼라제(goat) 억제제로 사용하기 위한 헤테로사이클릴-치환된 옥사디아졸로피리딘 유도체
JP7225253B2 (ja) 2018-02-02 2023-02-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのピラゾール置換及びインダゾール置換オキサジアゾロピリジン誘導体
US11583532B2 (en) 2018-02-02 2023-02-21 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (GOAT) inhibitors
MA53075A (fr) 2018-02-02 2021-05-12 Boehringer Ingelheim Int Dérivés d'oxadiazolopyridine à substitution benzyle, (pyridin-3-yl)méthyle ou (pyridin-4-yl)méthyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat)

Also Published As

Publication number Publication date
EA202091805A1 (ru) 2020-12-16
ECSP20050785A (es) 2020-09-30
MX2020008053A (es) 2020-09-07
CO2020009299A2 (es) 2020-08-21
CN111655700A (zh) 2020-09-11
CA3087826A1 (en) 2019-08-08
IL276136A (en) 2020-09-30
MA53075A (fr) 2021-05-12
JOP20200190A1 (ar) 2020-07-29
PE20210174A1 (es) 2021-01-29
CN111655700B (zh) 2023-07-18
US11254688B2 (en) 2022-02-22
WO2019149657A1 (en) 2019-08-08
EP3746451B1 (en) 2023-07-12
EP3746451A1 (en) 2020-12-09
CL2020001907A1 (es) 2020-10-30
BR112020013082A2 (pt) 2020-12-01
KR20200116978A (ko) 2020-10-13
JP7015396B2 (ja) 2022-02-15
AU2019215707A1 (en) 2020-07-09
JP2021512113A (ja) 2021-05-13
CR20200332A (es) 2020-09-03
US20210053985A1 (en) 2021-02-25
PH12020551168A1 (en) 2021-05-31

Similar Documents

Publication Publication Date Title
IL276136A (en) Benzyl, (pyridin-3-yl)methyl or (pyridin-4-yl)methyl-substituted oxadiazolopyridines as inhibitors of ghrelin O-acyltransferase
IL292643A (en) ras inhibitors
IL263163A (en) Pyridines are converted as inhibitors of dnmt1
DK3359541T3 (da) N-sulfonylerede pyrazol[3,4-b]pyridin-6-carboxamider og fremgangsmåde til anvendelse
IL284508A (en) Irreversible inhibitors of the MENIN-MLL interaction
SG11202003194YA (en) Methods for the administration of certain vmat2 inhibitors
PH12016500895B1 (en) Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
IL276145A (en) Triazolopyrimidine history for use as ghrelin O-acyltransferase inhibitors
IL281075A (en) Cardiac sarcomere inhibitors
HK1247613A1 (zh) 炔基吡啶類脯氨酰羥化酶抑制劑、其製備方法和醫藥用途
IL264506B (en) History of oxadiazolopyridine for use as gellin o-acyl transferase inhibitors
ZA201705675B (en) Ghrelin o-acyl transferase inhibitors
HK1245678A1 (zh) 使用酪氨酸激酶抑制劑的組合物和方法
IL276137A (en) Heterocyclyl-converted oxadiazolopyridine compounds for use as ghrelin O-acyltransferase inhibitors
ZA201705678B (en) Ghrelin o-acyl transferase inhibitors
ZA201900144B (en) Heat insulating coating composition, method for applying such coating composition and kit of parts comprising such coating composition
IL272939A (en) Vinyl heterocycles as RHO-linked coiled-coil kinase inhibitors
IL289993A (en) Ethynyl-heterocycles as rho-bound (rock) roller-bound kinase inhibitors
EP3176160A4 (en) Pyridine-substituted 2-aminopyridine protein kinase inhibitors
ZA201907272B (en) N-(4-pyridyl)nicotinamide compound or salt thereof
MX2016009435A (es) N-aril piridinonas sustituidas.
IL288950A (en) History of pyridine-3-yl
GB201810765D0 (en) SRPK1 inhibitors
GB201715637D0 (en) SRPK1 Inhibitors